Pub Date : 2025-11-01Epub Date: 2025-12-01DOI: 10.1016/j.canrad.2025.104771
Yasmine El Houat , Michel Lapeyre , Sophie Renard , Séverine Racadot , Laure Vieillevigne , Anouchka Modesto , Pierre Blanchard , Yoann Pointreau
Intensity-modulated conformal radiotherapy and brachytherapy are among the standard techniques for radiation treatments of oral cavity cancers. In this paper, each technique is detailed in terms of indications, treatment planning, volume delineation and selection, dosimetry, and position verification. This document represents an update of the Société française de radiothérapie oncologique (the French society for radiation oncology) guidelines (RecoRad™) for this anatomical site within the upper aerodigestive tract.
调强适形放疗和近距离放疗是口腔癌放射治疗的标准技术。在本文中，每种技术都详细介绍了适应症，治疗计划，体积划定和选择，剂量测定和位置验证。本文档是对法国放射肿瘤学学会（societyfranaise de radithrapie oncologique）指南（RecoRad™）的更新，该指南针对上气消化道内的该解剖部位。
{"title":"Radiotherapy for oral cavity cancers: 2025 update","authors":"Yasmine El Houat , Michel Lapeyre , Sophie Renard , Séverine Racadot , Laure Vieillevigne , Anouchka Modesto , Pierre Blanchard , Yoann Pointreau","doi":"10.1016/j.canrad.2025.104771","DOIUrl":"10.1016/j.canrad.2025.104771","url":null,"abstract":"<div><div>Intensity-modulated conformal radiotherapy and brachytherapy are among the standard techniques for radiation treatments of oral cavity cancers. In this paper, each technique is detailed in terms of indications, treatment planning, volume delineation and selection, dosimetry, and position verification. This document represents an update of the Société française de radiothérapie oncologique (the French society for radiation oncology) guidelines (RecoRad™) for this anatomical site within the upper aerodigestive tract.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104771"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-07DOI: 10.1016/j.canrad.2025.104761
Geneviève Loos , Alexandre Escande , Sabrina Aziez , Vincent Marchesi , Paul Sargos , Mario Terzilli , Igor Latorzeff , Stéphane Supiot , Vérane Achard , Jennifer Le Guévelou , Aude Flechon , Jean-Michel Hannoun-Lévi , Cyrus Chargari
This article presents an update of the French national guidelines for the management of penile cancer, with recommendations on dose and volume for radiotherapy and brachytherapy. Multidisciplinary management and centralization in high-level of expertise centres is key for the management of this rare malignancy. For patients at high-risk of having micrometastatic disease (stage T1b or higher), a dynamic sentinel node biopsy should be offered as surgical staging and human papillomavirus status should be obtained. Organ-preservation with brachytherapy should be discussed whenever it is possible (tumours limited to the glans). For locoregionally advanced diseases, chemoradiotherapy as primary treatment could be discussed.
{"title":"Radiotherapy for penile cancers: 2025 update","authors":"Geneviève Loos , Alexandre Escande , Sabrina Aziez , Vincent Marchesi , Paul Sargos , Mario Terzilli , Igor Latorzeff , Stéphane Supiot , Vérane Achard , Jennifer Le Guévelou , Aude Flechon , Jean-Michel Hannoun-Lévi , Cyrus Chargari","doi":"10.1016/j.canrad.2025.104761","DOIUrl":"10.1016/j.canrad.2025.104761","url":null,"abstract":"<div><div>This article presents an update of the French national guidelines for the management of penile cancer, with recommendations on dose and volume for radiotherapy and brachytherapy. Multidisciplinary management and centralization in high-level of expertise centres is key for the management of this rare malignancy. For patients at high-risk of having micrometastatic disease (stage T1b or higher), a dynamic sentinel node biopsy should be offered as surgical staging and human papillomavirus status should be obtained. Organ-preservation with brachytherapy should be discussed whenever it is possible (tumours limited to the glans). For locoregionally advanced diseases, chemoradiotherapy as primary treatment could be discussed.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104761"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145462448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-09-10DOI: 10.1016/j.canrad.2025.104713
Nicolas Benziane-Ouaritini , Jennifer Le Guevelou , Stéphane Supiot , Mario Terlizzi , Olivier Chapet , Idir Ouzaid , David Pasquier , Vincent Marchesi , Igor Latorzeff , Paul Sargos
Renal cell carcinoma represents the 14th most frequent tumour worldwide, but its incidence is increasing partly due to incidental diagnoses. As a result, these tumours are diagnosed in patients at an increasingly advanced age, often frail and with comorbidities. Most renal cell carcinoma cases are clear cell carcinoma (80 %), with papillary tumours being the second most frequent histological subtype. The standard of care for localized RCC is surgery, with partial nephrectomy or radical nephrectomy being recommended for T1 and T2 tumours, respectively. Thermoablative strategies have been developed over the past decade for patients who are not amenable to surgery and/or with impaired renal function. Active surveillance remains an alternative in the case of small low-grade renal cell carcinoma. Recent research has evaluated stereotactic ablative body radiotherapy as a well-tolerated and effective treatment for small renal tumours essentially for the management of both T1a and T1b tumours. This article aims to report the recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on the role of radiotherapy in the management of localized renal cell carcinoma. These guidelines describe both treatment planning modalities, target volumes, and follow-up procedures. They also focus on the impact of radiotherapy on renal function, and the specific dosimetric constraints to be implemented.
{"title":"Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology)","authors":"Nicolas Benziane-Ouaritini , Jennifer Le Guevelou , Stéphane Supiot , Mario Terlizzi , Olivier Chapet , Idir Ouzaid , David Pasquier , Vincent Marchesi , Igor Latorzeff , Paul Sargos","doi":"10.1016/j.canrad.2025.104713","DOIUrl":"10.1016/j.canrad.2025.104713","url":null,"abstract":"<div><div>Renal cell carcinoma represents the 14th most frequent tumour worldwide, but its incidence is increasing partly due to incidental diagnoses. As a result, these tumours are diagnosed in patients at an increasingly advanced age, often frail and with comorbidities. Most renal cell carcinoma cases are clear cell carcinoma (80 %), with papillary tumours being the second most frequent histological subtype. The standard of care for localized RCC is surgery, with partial nephrectomy or radical nephrectomy being recommended for T1 and T2 tumours, respectively. Thermoablative strategies have been developed over the past decade for patients who are not amenable to surgery and/or with impaired renal function. Active surveillance remains an alternative in the case of small low-grade renal cell carcinoma. Recent research has evaluated stereotactic ablative body radiotherapy as a well-tolerated and effective treatment for small renal tumours essentially for the management of both T1a and T1b tumours. This article aims to report the recommendations of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) on the role of radiotherapy in the management of localized renal cell carcinoma. These guidelines describe both treatment planning modalities, target volumes, and follow-up procedures. They also focus on the impact of radiotherapy on renal function, and the specific dosimetric constraints to be implemented.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104713"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145027042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-28DOI: 10.1016/j.canrad.2025.104769
Nicolas Martz , Jean Christophe Faivre , Guillaume Beldjoudi , Antoine Arnaud , Jérôme Chamois , Stéphane Supiot , Maximilien Rogé , Sébastien Thureau
We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical modalities of radiotherapy for bone metastases. This treatment is commonly used in the management of patients with cancer. In most cases, it involves relatively simple radiotherapy technique with proven efficacy in reducing pain or managing spinal cord compression. More complex treatments using stereotactic conditions can be proposed for patients with painful bone metastases, oligometastatic disease, or in case of reirradiation. In this context, increased vigilance must be given to the risks of spinal cord toxicity.
{"title":"Radiotherapy of bone metastases: 2025 update","authors":"Nicolas Martz , Jean Christophe Faivre , Guillaume Beldjoudi , Antoine Arnaud , Jérôme Chamois , Stéphane Supiot , Maximilien Rogé , Sébastien Thureau","doi":"10.1016/j.canrad.2025.104769","DOIUrl":"10.1016/j.canrad.2025.104769","url":null,"abstract":"<div><div>We present the updated recommendations of the Société française de radiothérapie oncologique (the French society for radiation oncology) regarding the indications and technical modalities of radiotherapy for bone metastases. This treatment is commonly used in the management of patients with cancer. In most cases, it involves relatively simple radiotherapy technique with proven efficacy in reducing pain or managing spinal cord compression. More complex treatments using stereotactic conditions can be proposed for patients with painful bone metastases, oligometastatic disease, or in case of reirradiation. In this context, increased vigilance must be given to the risks of spinal cord toxicity.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104769"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-09-16DOI: 10.1016/j.canrad.2025.104725
Cyrus Chargari , Anne Ducassou , Camille Roukoz , François Lucia , Adeline Petit , Abel Cordoba , Caroline Lafond , Sophie Renard , Alexandre Escande
Primary vaginal cancers are rare tumours, for which external beam radiotherapy and brachytherapy are major treatment tools. Given the complexity of brachytherapy techniques, the treatment should be performed in specialised centres. We present the 2025 update of recommendations of the Société française de radiothérapie oncologique on the indications and techniques for external beam radiotherapy and brachytherapy for primary vaginal cancer.
{"title":"Role of radiotherapy in the treatment of primary vaginal cancer: Recommendations of the Société française de radiothérapie oncologique, 2025 update","authors":"Cyrus Chargari , Anne Ducassou , Camille Roukoz , François Lucia , Adeline Petit , Abel Cordoba , Caroline Lafond , Sophie Renard , Alexandre Escande","doi":"10.1016/j.canrad.2025.104725","DOIUrl":"10.1016/j.canrad.2025.104725","url":null,"abstract":"<div><div>Primary vaginal cancers are rare tumours, for which external beam radiotherapy and brachytherapy are major treatment tools. Given the complexity of brachytherapy techniques, the treatment should be performed in specialised centres. We present the 2025 update of recommendations of the Société française de radiothérapie oncologique on the indications and techniques for external beam radiotherapy and brachytherapy for primary vaginal cancer.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104725"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-21DOI: 10.1016/j.canrad.2025.104770
Charles Raynaud , Maria Jolnerovski , Claire Lemanski , Benjamin Schipman , Laurence Moureau-Zabotto , Igor Bessières , Florence Huguet , Véronique Vendrely
We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding the use of external beam radiotherapy and brachytherapy in the management of anal cancer. Anal cancer is a rare malignancy with an increasing incidence, largely due to the high prevalence of Human papillomavirus infection. It primarily affects females over 65 years of age. The most common histological type is squamous cell carcinoma. The standard treatment involves a combination of intensity-modulated radiotherapy and concurrent chemotherapy with 5-fluorouracil (or capecitabine) and mitomycin. A localized boost dose to the tumour can be delivered either by external beam radiotherapy or brachytherapy. Recent studies have demonstrated that intensity-modulated radiotherapy helps avoid treatment interruptions, which are considered detrimental to efficacy. However, while radiotherapy achieves good outcomes for T1-T2 tumours without nodal involvement, T3-T4 stages or tumours with nodal involvement are associated with a poorer prognosis. Therefore, concomitant chemotherapy (5-fluorouracil or capecitabine with mitomycin) is recommended for tumours greater than 3 cm or those with nodal invasion. This approach remains a topic of debate for early-stage tumours. Target volumes, organs at risk delineation, doses, and fractionation regimens are discussed with respect to the balance between treatment efficacy and toxicity. Follow-up recommendations are provided to ensure early detection of cancer recurrence and late treatment-related side effects.
{"title":"Role of radiotherapy in the management of anal canal cancer: Recommendations of the Société française de radiothérapie oncologique","authors":"Charles Raynaud , Maria Jolnerovski , Claire Lemanski , Benjamin Schipman , Laurence Moureau-Zabotto , Igor Bessières , Florence Huguet , Véronique Vendrely","doi":"10.1016/j.canrad.2025.104770","DOIUrl":"10.1016/j.canrad.2025.104770","url":null,"abstract":"<div><div>We present the updated recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology) regarding the use of external beam radiotherapy and brachytherapy in the management of anal cancer. Anal cancer is a rare malignancy with an increasing incidence, largely due to the high prevalence of Human papillomavirus infection. It primarily affects females over 65<!--> <!-->years of age. The most common histological type is squamous cell carcinoma. The standard treatment involves a combination of intensity-modulated radiotherapy and concurrent chemotherapy with 5-fluorouracil (or capecitabine) and mitomycin. A localized boost dose to the tumour can be delivered either by external beam radiotherapy or brachytherapy. Recent studies have demonstrated that intensity-modulated radiotherapy helps avoid treatment interruptions, which are considered detrimental to efficacy. However, while radiotherapy achieves good outcomes for T1-T2 tumours without nodal involvement, T3-T4 stages or tumours with nodal involvement are associated with a poorer prognosis. Therefore, concomitant chemotherapy (5-fluorouracil or capecitabine with mitomycin) is recommended for tumours greater than 3<!--> <!-->cm or those with nodal invasion. This approach remains a topic of debate for early-stage tumours. Target volumes, organs at risk delineation, doses, and fractionation regimens are discussed with respect to the balance between treatment efficacy and toxicity. Follow-up recommendations are provided to ensure early detection of cancer recurrence and late treatment-related side effects.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104770"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<div><div>We present the update of the recommendations of the Société française de radiothérapie oncologique on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumours can be treated by exclusive radiation or surgery followed by postoperative radiation in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, they can be treated by chemoradiation or by induction drugs followed by exclusive radiation. For T4 tumour, surgery must be proposed. Different fractionation schedules are possible: for 35 fractions, the curative dose is 70<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction) and prophylactic doses are 50 to 56<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction in case of sequential radiotherapy or 1.6<!--> <!-->Gy in case of simultaneous integrated boost radiotherapy; for 33 fractions, the curative dose is 69.96<!--> <!-->Gy (delivered at 2.12<!--> <!-->Gy per fraction) and the prophylactic dose is 52.8<!--> <!-->Gy (delivered at 1.6<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy or 54<!--> <!-->Gy in 1.64<!--> <!-->Gy per fraction); for 30 fractions, curative dose is 66<!--> <!-->Gy (delivered at 2.2<!--> <!-->Gy per fraction) and prophylactic dose is 54<!--> <!-->Gy (delivered at 1.8<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy. Doses over 2<!--> <!-->Gy per fraction can be delivered when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used for locally advanced cancer with dose levels based on pathologic criteria, delivering 60 to 66<!--> <!-->Gy for R1 resection and 57.6 to 60<!--> <!-->Gy for complete resection in bed tumour; 50 to 66<!--> <!-->Gy in lymph nodes areas regarding extracapsular spread. Target volume delineation recommendations were based on guidelines cited in this article.</div></div><div><div>Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique concernant la radiothérapie du cancer de l’hypopharynx. La radiothérapie conformationnelle avec modulation d’intensité est le traitement de référence pour les cancers de l’hypopharynx. Les tumeurs de stade précoce (T1 et T2) peuvent être traitées soit par irradiation exclusive soit par chirurgie suivie d’une irradiation postopératoire en cas de risque élevé de récidive. Pour les tumeurs localement évoluées nécessitant une pharyngolaryngectomie totale (T2 ou T3) ou avec un envahissement ganglionnaire significatif, elles peuvent être prises en charge d’emblée par une chimioradiothérapie concomitante ou par une chimiothérapie d’induction suivie d’une radiothérapie exclusive. Pour les tumeurs de stade T4, la chirurgie doit être proposée. Différents schémas de fractionnement sont envisageables: en 35 fractions, la dose à visée curative est de 70<!-->
{"title":"Radiotherapy for hypopharynx cancers: 2025 update","authors":"Dylan Bocha , Julian Biau , Alexandre Coutte , Andrès Huertas , Nolwenn Delaby , Michel Lapeyre , Pierre Blanchard , Yoann Pointreau","doi":"10.1016/j.canrad.2025.104755","DOIUrl":"10.1016/j.canrad.2025.104755","url":null,"abstract":"<div><div>We present the update of the recommendations of the Société française de radiothérapie oncologique on radiotherapy for hypopharynx. Intensity-modulated radiotherapy is the gold standard treatment for hypopharynx cancers. Early T1 and T2 tumours can be treated by exclusive radiation or surgery followed by postoperative radiation in case of high recurrence risk. For locally advanced tumours requiring total pharyngolaryngectomy (T2 or T3) or with significant lymph nodes involvement, they can be treated by chemoradiation or by induction drugs followed by exclusive radiation. For T4 tumour, surgery must be proposed. Different fractionation schedules are possible: for 35 fractions, the curative dose is 70<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction) and prophylactic doses are 50 to 56<!--> <!-->Gy (delivered at 2<!--> <!-->Gy per fraction in case of sequential radiotherapy or 1.6<!--> <!-->Gy in case of simultaneous integrated boost radiotherapy; for 33 fractions, the curative dose is 69.96<!--> <!-->Gy (delivered at 2.12<!--> <!-->Gy per fraction) and the prophylactic dose is 52.8<!--> <!-->Gy (delivered at 1.6<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy or 54<!--> <!-->Gy in 1.64<!--> <!-->Gy per fraction); for 30 fractions, curative dose is 66<!--> <!-->Gy (delivered at 2.2<!--> <!-->Gy per fraction) and prophylactic dose is 54<!--> <!-->Gy (delivered at 1.8<!--> <!-->Gy per fraction in simultaneous integrated boost radiotherapy. Doses over 2<!--> <!-->Gy per fraction can be delivered when chemotherapy is not used regarding potential larynx toxicity. Postoperatively, radiotherapy is used for locally advanced cancer with dose levels based on pathologic criteria, delivering 60 to 66<!--> <!-->Gy for R1 resection and 57.6 to 60<!--> <!-->Gy for complete resection in bed tumour; 50 to 66<!--> <!-->Gy in lymph nodes areas regarding extracapsular spread. Target volume delineation recommendations were based on guidelines cited in this article.</div></div><div><div>Nous présentons la mise à jour des recommandations de la Société française de radiothérapie oncologique concernant la radiothérapie du cancer de l’hypopharynx. La radiothérapie conformationnelle avec modulation d’intensité est le traitement de référence pour les cancers de l’hypopharynx. Les tumeurs de stade précoce (T1 et T2) peuvent être traitées soit par irradiation exclusive soit par chirurgie suivie d’une irradiation postopératoire en cas de risque élevé de récidive. Pour les tumeurs localement évoluées nécessitant une pharyngolaryngectomie totale (T2 ou T3) ou avec un envahissement ganglionnaire significatif, elles peuvent être prises en charge d’emblée par une chimioradiothérapie concomitante ou par une chimiothérapie d’induction suivie d’une radiothérapie exclusive. Pour les tumeurs de stade T4, la chirurgie doit être proposée. Différents schémas de fractionnement sont envisageables: en 35 fractions, la dose à visée curative est de 70<!--> ","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104755"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145305062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-21DOI: 10.1016/j.canrad.2025.104774
Delphine Antoni , Emmanuel Mesny , Osman El Kabbaj , Charlotte Robert , Kévin Quintin , Loïc Feuvret , Julian Biau , Julian Jacob
Gliomas are the most frequent malignant primary brain tumours in adults. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, Karnofsky performance status) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiotherapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential; they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and the technical procedures for performing radiotherapy in patients with gliomas.
{"title":"Radiotherapy guidelines for gliomas: 2025 update","authors":"Delphine Antoni , Emmanuel Mesny , Osman El Kabbaj , Charlotte Robert , Kévin Quintin , Loïc Feuvret , Julian Biau , Julian Jacob","doi":"10.1016/j.canrad.2025.104774","DOIUrl":"10.1016/j.canrad.2025.104774","url":null,"abstract":"<div><div>Gliomas are the most frequent malignant primary brain tumours in adults. The proximity of organs at risk, the infiltrating nature, and the radioresistance of gliomas have to be taken into account in the choice of prescribed dose and technique of radiotherapy. The management of glioma patients is based on clinical factors (age, Karnofsky performance status) and tumour characteristics (histology, molecular biology, tumour location), and strongly depends on available and associated treatments, such as surgery, radiotherapy, and chemotherapy. The knowledge of molecular biomarkers is currently essential; they are increasingly evolving as additional factors that facilitate diagnostics and therapeutic decision-making. We present the update of the recommendations of the Société française de radiothérapie oncologique (the French Society for Radiation Oncology) on the indications and the technical procedures for performing radiotherapy in patients with gliomas.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104774"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01Epub Date: 2025-11-24DOI: 10.1016/j.canrad.2025.104778
Yuedan Zhou , Alexandre Escande , David Pasquier , Cyrus Chargari , Myriam Ayadi , Jonathan Khalifa , Delphine Antoni , Igor Latorzeff , Valentine Guimas , Véronique Vendrely , Arnaud Beddok , Stéphane Supiot
The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized and prospective data, an increasing number of clinical guidelines encourage its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, the following publication is based on the guidelines and multicentre reflections of the Recommendations Commission of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on prostate, gynaecological and pelvic tumours.
{"title":"Reirradiation of prostate, gynaecologic and pelvic tumours, suggestions from the Recommendations Commission of the Société française de radiothérapie oncologique","authors":"Yuedan Zhou , Alexandre Escande , David Pasquier , Cyrus Chargari , Myriam Ayadi , Jonathan Khalifa , Delphine Antoni , Igor Latorzeff , Valentine Guimas , Véronique Vendrely , Arnaud Beddok , Stéphane Supiot","doi":"10.1016/j.canrad.2025.104778","DOIUrl":"10.1016/j.canrad.2025.104778","url":null,"abstract":"<div><div>The process of reirradiation in oncology presents a distinctive set of challenges, wherein clinical decision-making is predicated on a delicate balancing act between the efficacy of the treatment and the risk of severe toxicity. Despite the paucity of randomized and prospective data, an increasing number of clinical guidelines encourage its consideration for patients with local or metastatic recurrence. While awaiting dedicated guidance from international scientific societies, the following publication is based on the guidelines and multicentre reflections of the Recommendations Commission of the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology). It addresses key questions related to reirradiation, with a particular focus on prostate, gynaecological and pelvic tumours.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104778"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The personalization of oncology and radiation treatments is becoming increasingly crucial in patient care. Over the past few decades, numerous assays have been developed to predict tumour response and assess the risk of radiation-induced toxicity. These tests have not yet been integrated into routine clinical practice, but recent advances in radiation oncology are paving the way for personalized strategies that consider both tumour recurrence risk and normal tissue reactions. Regarding tumour radiosensitivity prediction, no tests are currently in clinical use, although the radiosensitivity index and Genome-based Model for Adjusting Radiotherapy Dose assays appear to be the most promising, with level II evidence. Development of radiomics has also made it possible to envisage new biomarkers. Prospective studies are ongoing. For normal tissue radiosensitivity prediction, single nucleotide polymorphims in prostate cancer and head and neck cancer patients, and the radiation-induced CD8 T-lymphocyte apoptosis assay for breast and prostate cancers are supported by level I evidence. These tests can be offered prior to the initiation of radiotherapy to tailor treatments based on both tumour and normal tissue radiosensitivity risks.
{"title":"Tumour and normal tissue radiosensitivity: 2025 update","authors":"Ariane Lapierre , Jeanne Monge-Cadet , Muriel Brengues , Igor Bessières , Laurent Quéro , Céline Mirjolet , Olivier Riou","doi":"10.1016/j.canrad.2025.104720","DOIUrl":"10.1016/j.canrad.2025.104720","url":null,"abstract":"<div><div>The personalization of oncology and radiation treatments is becoming increasingly crucial in patient care. Over the past few decades, numerous assays have been developed to predict tumour response and assess the risk of radiation-induced toxicity. These tests have not yet been integrated into routine clinical practice, but recent advances in radiation oncology are paving the way for personalized strategies that consider both tumour recurrence risk and normal tissue reactions. Regarding tumour radiosensitivity prediction, no tests are currently in clinical use, although the radiosensitivity index and Genome-based Model for Adjusting Radiotherapy Dose assays appear to be the most promising, with level II evidence. Development of radiomics has also made it possible to envisage new biomarkers. Prospective studies are ongoing. For normal tissue radiosensitivity prediction, single nucleotide polymorphims in prostate cancer and head and neck cancer patients, and the radiation-induced CD8 T-lymphocyte apoptosis assay for breast and prostate cancers are supported by level I evidence. These tests can be offered prior to the initiation of radiotherapy to tailor treatments based on both tumour and normal tissue radiosensitivity risks.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 7","pages":"Article 104720"},"PeriodicalIF":1.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145045189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号